Insights

Emerging Stem Cell Platform StemBioSys has developed a proprietary 3D stem cell culture technology, CELLvo Matrix, which enhances the isolation, growth, and expansion of difficult-to-culture stem cells from various sources. This versatile platform presents opportunities to sell research reagents, customized cell culture products, and licensing or partnership deals to biotech and research institutions focusing on regenerative medicine.

Strategic Partnerships & Distribution The company has established key agreements with organizations such as VWR International and GenCure Biomanufacturing, indicating strong distribution channels and collaborative development potential. These partnerships can be leveraged to broaden market reach for CELLvo products and explore co-marketing or licensing opportunities in the life sciences supply chain.

Product Innovation & Expansion Recent launches of specialized cell types like the CELLvo Atrial Cardiomyocytes and culture systems for chondrocytes demonstrate a focus on expanding product offerings for targeted research applications. This creates prospects to engage with pharmaceutical and biotech clients developing cell therapies, disease models, and personalized medicine solutions.

Funding & Growth Potential With recent Series B funding of over 8 million dollars and a revenue range between 1 million and 10 million dollars, StemBioSys is positioned for rapid growth. This capital infusion supports scaling manufacturing capabilities and accelerating sales efforts targeted at research institutes, biotech firms, and clinical research organizations investing in advanced cell culture technologies.

Market Position & Opportunities While competing with firms like STEMCELL Technologies and MilliporeSigma, StemBioSys’s innovative tissue-mimicking matrices and expanding product line position it as a disruptive player in stem cell research tools. Business development efforts can focus on differentiating the company’s proprietary tech for niche markets such as regenerative medicine, cell therapies, and specialized research applications.

StemBioSys, Inc. Tech Stack

StemBioSys, Inc. uses 8 technology products and services including Hotjar, W3 Total Cache, JSON-LD, and more. Explore StemBioSys, Inc.'s tech stack below.

  • Hotjar
    Analytics
  • W3 Total Cache
    Caching
  • JSON-LD
    Javascript Frameworks
  • Element UI
    Javascript Frameworks
  • React
    Javascript Frameworks
  • PHP
    Programming Languages
  • YouTube
    Video Players
  • Google Analytics
    Web Analytics

Media & News

StemBioSys, Inc.'s Email Address Formats

StemBioSys, Inc. uses at least 1 format(s):
StemBioSys, Inc. Email FormatsExamplePercentage
First.Last@stembiosys.comJohn.Doe@stembiosys.com
48%
First@stembiosys.comJohn@stembiosys.com
2%
FLast@stembiosys.comJDoe@stembiosys.com
2%
First.Last@stembiosys.comJohn.Doe@stembiosys.com
48%

Frequently Asked Questions

Where is StemBioSys, Inc.'s headquarters located?

Minus sign iconPlus sign icon
StemBioSys, Inc.'s main headquarters is located at 3463 Magic Drive, Suite 110, San Antonio, Texas 78229, US. The company has employees across 1 continents, including North America.

What is StemBioSys, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact StemBioSys, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is StemBioSys, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
StemBioSys, Inc.'s official website is stembiosys.com and has social profiles on LinkedInCrunchbase.

What is StemBioSys, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
StemBioSys, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does StemBioSys, Inc. have currently?

Minus sign iconPlus sign icon
As of October 2025, StemBioSys, Inc. has approximately 11 employees across 1 continents, including North America. Key team members include Chief Financial Officer: M. H.President & Ceo; Member Of The Board Of Directors: R. H.Senior Director Of Global Sales: I. F.. Explore StemBioSys, Inc.'s employee directory with LeadIQ.

What industry does StemBioSys, Inc. belong to?

Minus sign iconPlus sign icon
StemBioSys, Inc. operates in the Biotechnology Research industry.

What technology does StemBioSys, Inc. use?

Minus sign iconPlus sign icon
StemBioSys, Inc.'s tech stack includes HotjarW3 Total CacheJSON-LDElement UIReactPHPYouTubeGoogle Analytics.

What is StemBioSys, Inc.'s email format?

Minus sign iconPlus sign icon
StemBioSys, Inc.'s email format typically follows the pattern of First.Last@stembiosys.com. Find more StemBioSys, Inc. email formats with LeadIQ.

How much funding has StemBioSys, Inc. raised to date?

Minus sign iconPlus sign icon
As of October 2025, StemBioSys, Inc. has raised $4.1M in funding. The last funding round occurred on May 15, 2018 for $4.1M.

When was StemBioSys, Inc. founded?

Minus sign iconPlus sign icon
StemBioSys, Inc. was founded in 2010.

StemBioSys, Inc.

Biotechnology ResearchUnited States11-50 Employees

StemBioSys is located in San Antonio, Texas and proximate to the University of Texas Health Science Center San Antonio (UTHSC-SA) from which we have licensed proprietary and disruptive technology for the enhanced isolation, growth and delivery of stem cells or other difficult to culture cells for research, diagnostic and therapeutic applications.

We are currently focused on scale-up activities for our patented core technology, CELLvo™ Matrix and our initial product launch to the stem cell research market in mid-2015. Build-out of our cGMP facility with partner BioBridge Global is complete and we have begun to explore therapeutic applications and business relationships with potential partners for other, next generation, product offerings from this versatile platform technology.

Our core novel technology platform is an advanced stem cell culture system – CELLvo™ Matrix. CELLvo Matrix™ replicates the 3-dimensional “home” in which stem cells naturally reside and proliferate. Stem cells grown in BM-HPME™ remain small, proliferative and undifferentiated. Our unique technology enables users to isolate and grow stem cells and other difficult to culture cells from a variety of sources including but not limited to adipose, bone marrow and umbilical cord blood/tissue and cancer cells.

Stem cells are the future of medicine. We are the future of stem cells. We will build value for our shareholders by perfecting and focusing on the use of our disruptive stem cell technology platforms, know-how and intellectual property for the treatment of meaningful medical disorders. We will establish the facilities, expertise, discipline and culture required to assure our patients, physicians, researchers and partners that everything we do will conform to the highest standards of quality.

Section iconCompany Overview

Headquarters
3463 Magic Drive, Suite 110, San Antonio, Texas 78229, US
Phone number
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2010
Employees
11-50

Section iconFunding & Financials

  • $4.1M

    StemBioSys, Inc. has raised a total of $4.1M of funding over 3 rounds. Their latest funding round was raised on May 15, 2018 in the amount of $4.1M.

  • $1M$10M

    StemBioSys, Inc.'s revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $4.1M

    StemBioSys, Inc. has raised a total of $4.1M of funding over 3 rounds. Their latest funding round was raised on May 15, 2018 in the amount of $4.1M.

  • $1M$10M

    StemBioSys, Inc.'s revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.